SG11201803808VA - 1,3,4-thiadiazole compounds and their use in treating cancer - Google Patents

1,3,4-thiadiazole compounds and their use in treating cancer

Info

Publication number
SG11201803808VA
SG11201803808VA SG11201803808VA SG11201803808VA SG11201803808VA SG 11201803808V A SG11201803808V A SG 11201803808VA SG 11201803808V A SG11201803808V A SG 11201803808VA SG 11201803808V A SG11201803808V A SG 11201803808VA SG 11201803808V A SG11201803808V A SG 11201803808VA
Authority
SG
Singapore
Prior art keywords
international
astrazeneca
cambridge
park
cheshire
Prior art date
Application number
SG11201803808VA
Other languages
English (en)
Inventor
Maurice Finlay
David Perkins
Johannes Nissink
Piotr Raubo
Peter Smith
Andrew Bailey
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of SG11201803808VA publication Critical patent/SG11201803808VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201803808VA 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer SG11201803808VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260784P 2015-11-30 2015-11-30
PCT/EP2016/079253 WO2017093301A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
SG11201803808VA true SG11201803808VA (en) 2018-06-28

Family

ID=57460503

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803808VA SG11201803808VA (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Country Status (28)

Country Link
US (1) US10040789B2 (es)
EP (1) EP3383872B1 (es)
JP (1) JP6821680B2 (es)
KR (1) KR20180083411A (es)
CN (1) CN108349965B (es)
AR (1) AR106875A1 (es)
AU (1) AU2016361834B2 (es)
BR (1) BR112018008330B1 (es)
CA (1) CA3005517C (es)
CL (1) CL2018001409A1 (es)
CO (1) CO2018006930A2 (es)
DK (1) DK3383872T3 (es)
DO (1) DOP2018000135A (es)
EA (1) EA035519B9 (es)
ES (1) ES2796562T3 (es)
IL (1) IL259508A (es)
MX (1) MX2018006483A (es)
MY (1) MY195680A (es)
NI (1) NI201800063A (es)
NZ (1) NZ743699A (es)
PE (1) PE20181522A1 (es)
PH (1) PH12018501133A1 (es)
SG (1) SG11201803808VA (es)
SV (1) SV2018005700A (es)
TN (1) TN2018000118A1 (es)
TW (1) TW201731511A (es)
WO (1) WO2017093301A1 (es)
ZA (1) ZA201804361B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
EP3868758B1 (en) * 2018-10-16 2023-01-04 Medshine Discovery Inc. Thiadiazole derivatives and use thereof as a gls1 inhibitors for the treatment of cancer
CN114560855B (zh) * 2021-03-26 2023-05-23 成都苑东生物制药股份有限公司 环烷基甲酰胺类衍生物、其制备方法及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2782570T1 (sl) 2011-11-21 2020-02-28 Calithera Biosciences Inc. Heterociklični inhibitorji glutaminaze
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
EA033163B1 (ru) 2014-01-06 2019-09-30 Ризен Фармасьютикалз Са Ингибиторы глутаминазы
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
EP3383872A1 (en) 2018-10-10
PH12018501133A1 (en) 2019-01-21
JP2018535235A (ja) 2018-11-29
KR20180083411A (ko) 2018-07-20
US10040789B2 (en) 2018-08-07
AR106875A1 (es) 2018-02-28
SV2018005700A (es) 2019-03-07
EA201891239A1 (ru) 2018-11-30
CA3005517C (en) 2023-12-12
CA3005517A1 (en) 2017-06-08
AU2016361834A1 (en) 2018-07-12
JP6821680B2 (ja) 2021-01-27
NI201800063A (es) 2018-10-18
CN108349965A (zh) 2018-07-31
US20170333429A1 (en) 2017-11-23
DK3383872T3 (da) 2020-06-08
TN2018000118A1 (en) 2019-10-04
BR112018008330B1 (pt) 2023-03-07
CO2018006930A2 (es) 2018-10-10
MY195680A (en) 2023-02-03
CL2018001409A1 (es) 2018-12-07
ES2796562T3 (es) 2020-11-27
WO2017093301A1 (en) 2017-06-08
PE20181522A1 (es) 2018-09-24
DOP2018000135A (es) 2018-06-30
BR112018008330A2 (pt) 2018-10-30
AU2016361834B2 (en) 2019-11-14
TW201731511A (zh) 2017-09-16
EA035519B1 (ru) 2020-06-29
ZA201804361B (en) 2019-07-31
EA035519B9 (ru) 2020-08-10
EP3383872B1 (en) 2020-05-20
IL259508A (en) 2018-07-31
NZ743699A (en) 2023-02-24
MX2018006483A (es) 2019-08-12
CN108349965B (zh) 2021-10-26

Similar Documents

Publication Publication Date Title
SG11201803808VA (en) 1,3,4-thiadiazole compounds and their use in treating cancer
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201908598PA (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201805838UA (en) Macrocyclic mcl1 inhibitors for treating cancer
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201804934PA (en) Novel Compounds
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201809342YA (en) Pyrimidine compounds as jak kinase inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201811074RA (en) Nant cancer vaccine
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201810970WA (en) Anti-egfr antibody drug conjugates
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201805154YA (en) Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201407729VA (en) Methods for drug screen using zebrafish model and the compounds screened thereform
SG11201407402TA (en) Carbazole-containing sulfonamides as cryptochrome modulators
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201900689RA (en) Compounds and compositions and uses thereof
SG11201903348UA (en) Therapeutic compounds and methods of use thereof
SG11201909224QA (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase